<unk> , sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.<unk>  was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.<unk>  was granted an emergency use authorization (EUA) for the treatment of COVID-19 in the United States in June 2021.
Tocilizumab
Satralizumab
Brolucizumab
Ixekizumab
Caplacizumab
Atezolizumab
Reslizumab
Risankizumab